Promoting an incLUsive Society Towards Older Adults With Physical Disabilities

April 11, 2024 updated by: Suzanne HS Lo, Chinese University of Hong Kong

Promoting an incLUsive Society Towards Older Adults With Physical Disabilities Through Disability Simulation Education (PLUS)

To improve secondary school students' positive attitudes towards older adults with physical disabilities via a Promoting an incLUsive Society towards older adults with physical disabilities through disability simulation education (PLUS) project.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

A pretest-posttest and qualitative study design will be adopted. 1,000 junior secondary students will be recruited from six secondary schools in Hong Kong by convenience sampling to participate in a 3-day PLUS Convention. Changes in students' attitudes towards older adults with physical disabilities and satisfaction with life, and their satisfaction with the disability simulation experience will be assessed. Semi-structured interviews will be conducted with students, facilitators, teachers, and older adults with physical disabilities to gain further feedback.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1111

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Hong Kong
      • Hong Kong, Hong Kong
        • Secondary schools

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

12 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. currently a secondary 1 to secondary 3 student
  2. studying in a secondary school in Hong Kong
  3. communicable in Cantonese
  4. willing to attend all of the activities of the 3-day PLUS Convention

Exclusion Criteria:

  1. have a physical or learning disability
  2. diagnosed with a severe psychiatric illness

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: 3-day PLUS Convention
Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, service-learning seminar, disability simulation workshop, and two community contact sessions.
Behavioral: 3-day PLUS Convention
Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, a service-learning seminar, a disability simulation workshop, and two community contact sessions which will consist of a 60-minute interview with an older adult with a physical disability and an outdoor experience. Discussion sessions will be facilitated throughout to consolidate learning.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in the participants' attitudes towards older adults with physical disabilities
Time Frame: Change from baseline to immediately after completion of the intervention (2 months)
The 47-item Students' Attitudes toward People with a Disability Scale will be used. It was developed locally in the Baseline Survey of Students' Attitudes towards People with a Disability, a study conducted by the Equal Opportunities Commission in Hong Kong. It encompasses four attitude sub-scales, namely social acceptance, behavioural misconceptions, pessimism-hopelessness, and optimism-human rights. Participants will rate their agreement with each item on a 4-point Likert scale (1 = "Strongly agree" - 4 = "Strongly disagree"). The four attitude sub-scale scores will then be converted along a scale between 1-100. A higher score will indicate a more positive attitude towards people with a disability. All sub-scales had Cronbach's Alpha scores ranging from 0.69 to 0.85, which support their respectable reliability.
Change from baseline to immediately after completion of the intervention (2 months)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in the participants' level of life satisfaction
Time Frame: Change from baseline to immediately after completion of the intervention (2 months)
The 5-item Satisfaction With Life Scale (SWLS) will be adopted. Participants will rate their overall judgement of their life on a 7-point Likert scale (1 = "Strongly disagree" - 7 = "Strongly agree"). The total score ranges from 5 to 35 points, with a higher score indicating a higher satisfaction with life. The SWLS has a Cronbach's Alpha score of 0.87, supporting its internal consistency and reliability.
Change from baseline to immediately after completion of the intervention (2 months)
The participants' level of satisfaction with the disability simulation workshop
Time Frame: Immediately after completion of the disability simulation workshop (within 1 day)
The 18-item Satisfaction with Disability Simulation Experience Scale (SDSES) will be used. Participants will rate their extent of agreement with the simulations using a 5-point Likert scale (1 = "Strongly disagree" - 5 = "Strongly agree") to indicate their satisfaction with them. A higher score will indicate higher satisfaction with the simulation experience. The survey will have one open-ended question asking students to provide additional comments about their simulation experience. The scale's internal consistency reliability is supported as its whole Cronbach's coefficient values ranged from 0.70 to 0.88.
Immediately after completion of the disability simulation workshop (within 1 day)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Chinese University of Hong Kong

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Suzanne Lo, Chinese University of Hong Kong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 31, 2023

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 31, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 21, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 28, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 6, 2021

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 15, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 11, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • PLUS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The datasets used and/or analysed during the current study will be available from the corresponding author on reasonable request.

IPD Sharing Time Frame

The datasets used and/or analysed during the current study will be available from the corresponding author, on reasonable request, for six years upon completion of the study

IPD Sharing Access Criteria

The datasets used and/or analysed during the current study will be available from the corresponding author on reasonable request.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Disability Physical

Clinical Trials on 3-day PLUS Convention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings